

BREAST

A011502 (ABC) - A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer Criteria: Node Positive HER2 Negative Breast Cancer

A011401 - Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

A221505 - Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast. Criteria: Post Mastectomy Radiation Therapy with Breast Reconstruction

S1418/NRG-BR006 - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy. Criteria: Triple Negative Breast Cancer with Residual Invasive Cancer or Positive Lymph Nodes

EA1131 - A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy Residual

COLON

A021502 - Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy Criteria: Stage III Colon Cancer and Deficient DNA Mismatch Repair.

OVARIAN

NRG-GY005 - Randomized Phase III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS). Criteria: Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

LUNG

A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial. Criteria: Patients With Resectable or Resected Lung Cancer

A081105 - Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer

E4512 - A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

EA5142 - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

CALGB 30610 - Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

NRG-LU002 - Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC)

NRG-CC003 - Randomized Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

LungMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

PROSTATE

NRG-GU002 - Phase II/III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following RP with or without Adjuvant Docetaxel Criteria: Post Radical Prostatectomy Radiotherapy and Androgen Deprivation

NRG-GU005 - Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

All Types of Cancers

Communication Skills Training for Cancer Patients and their Care Partners.
Johns Hopkins Clinical Research Network